DDIT4 and triple-negative breast carcinoma: Knocking down DDIT4 significantly inhibits the tumor progression of triple-negative breast cancer both in vitro and in vivo, and inhibiting DDIT4 can enhance the efficacy of paclitaxel in patients with triple-negative breast cancer (36).